May 4, 2020 / 12:12 PM / a month ago

BRIEF-VBL First-In-Class Mospd2 Antibodies Show Potential For Treatment For Cns Inflammation

May 4 (Reuters) - Vascular Biogenics Ltd:

* VBL FIRST-IN-CLASS MOSPD2 ANTIBODIES SHOW POTENTIAL FOR TREATMENT FOR CNS INFLAMMATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below